To the Editor:

Coronavirus disease (COVID-19) spreads rapidly and has already resulted in severe burden to hospitals and ICUs worldwide. Early reports described progression to acute respiratory distress syndrome (ARDS) in 29% of cases (1).

It is unknown how to titrate positive end-expiratory pressure (PEEP) in patients with ARDS. Patient survival improved if higher PEEP successfully recruited atelectatic lung tissue (2). However, excessive PEEP caused alveolar overdistention, resulting in reduced patient survival (3). Therefore, PEEP should be personalized to maximize alveolar recruitment and minimize the amount of alveolar overdistention. Electrical impedance tomography (EIT) provides a reliable bedside approach to detect both alveolar overdistention and alveolar collapse (4).

We describe a case series of patients with COVID-19 and moderate to severe ARDS in whom EIT was applied to personalize PEEP based on the lowest relative alveolar overdistention and collapse. Subsequently, we compared this PEEP level with the PEEP that could have been set according to the lower or higher PEEP–FiO2 table from the ALVEOLI trial (5). These early experiences may help clinicians to titrate PEEP in patients with COVID-19 and ARDS.

Methods

Study design and inclusion criteria. We conducted this case series between March 1, 2020, and March 31, 2020, in our tertiary referral ICU (Erasmus Medical Center, Rotterdam, the Netherlands). All consecutive mechanically ventilated patients admitted to the ICU with COVID-19 and moderate to severe ARDS (according to the Berlin definition of ARDS) were included in this study. COVID-19 was defined as a positive result on a PCR of sputum, nasal swab, or pharyngeal swab specimen. The local medical ethical committee approved this study. Informed consent was obtained from all patients’ legal representatives.

Study protocol. A PEEP trial was performed daily in all patients according to our local mechanical ventilation protocol. Patients were fully sedated with continuous intravenous infusion of propofol, midazolam, and opiates. Persisting spontaneous breathing efforts were prevented with increased sedation or neuromuscular blockade. Arterial blood pressure was measured continuously. Noradrenalin was titrated to maintain a mean arterial blood pressure above 65 mm Hg at the start of the PEEP trial.

All patients were ventilated in pressure-control mode. FiO2 was titrated to obtain a peripheral oxygen saturation between 92% and 95%. The other mechanical ventilation parameters (i.e., PEEP driving pressure, respiratory rate, and inspiratory/expiratory ratio) remained unchanged. Plateau airway pressure and total PEEP were measured during a zero-flow state with an inspiratory and expiratory hold procedure, respectively. Absolute transpulmonary pressures were measured with an esophageal balloon catheter (CooperSurgical or NutriVent). The position and balloon inflation status were tested with chest compression during an expiratory hold maneuver.

We monitored bedside ventilation distribution with EIT (Pulmovista 500; Dräger or Enlight 1800; Timpel). An EIT belt was placed around the patient’s thorax in the transversal plane corresponding with the fourth to fifth intercostal parasternal space. The belt was placed daily (Pulmovista) or once in 3 days (Enlight), according to manufacturer’s instructions. EIT data were visualized on screen during the entire study protocol without repositioning the EIT belt.

Subsequently, we performed a decremental PEEP trial. The PEEP was increased stepwise until the PEEP was 10 cm H2O above the baseline PEEP with a minimum PEEP of 24 cm H2O (PEEPhigh), corresponding with the maximum PEEP advised by the PEEP–FiO2 table. The PEEP trial was limited to a lower PEEP level in case of hypotension (mean arterial blood pressure < 60 mm Hg) or desaturation (peripheral oxygen saturation < 88%). PEEPhigh was maintained for at least 1 minute. From PEEPhigh, the PEEP was reduced in 2–cm H2O steps of 30 seconds until the EIT showed evident collapse. The PEEP was reduced an additional 2 cm H2O to confirm a further increase in collapse. The EIT devices provided percentages of relative alveolar overdistention and collapse at every PEEP step. Lastly, the total PEEP was set (PEEPset) at the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse (Figure 1) (6).

Baseline characteristics and laboratory analyses were retrieved from the patient information system. Diffuse or focal ARDS was established with chest X-ray or lung computed tomography (CT) scan, similar to the LIVE (Lung Imaging for Ventilatory Setting in ARDS) study (7).

Statistical analysis. Data were presented as medians and interquartile ranges (IQRs). Only PEEPset as determined by the first PEEP trial, of each patient was used for analyses. The absolute distance in cm H2O between PEEPset and the closest PEEP level that could have been set based on the lower PEEP–FiO2 table or the higher PEEP–FiO2 table from the ALVEOLI trial was calculated (5). The Wilcoxon signed-rank test was used to test the difference between PEEPset and the absolute distance to either the PEEP–FiO2 table and to test the difference in PEEPset between the first and last PEEP trial (up to Day 7). Correlations were assessed using Spearman’s rank correlation coefficient (ρ).

Results

Study population. We included 15 patients with COVID-19–related ARDS (Table 1). Patients had a body mass index (BMI) of 30 kg/m² (IQR, 27–34 cm H2O). All patients had high concentrations of C-reactive protein and required vasopressors during the first
week after ICU admission. In addition, 14 (93%) patients had or progressed to diffuse ARDS on their chest X-ray or lung CT scan.

**PEEP** set in COVID-19–related ARDS. We conducted a total of 63 PEEP trials, of which 52 were performed in the supine position. The median amount of PEEP trials per patient was 3 (IQR, 2–4.5). PEEP set based on EIT was 21 cm H\(_2\)O (IQR, 16–22 cm H\(_2\)O). Driving pressure was below 13 cm H\(_2\)O in all patients (Table 1). In one PEEP trial (1.6%), we did not reach a PEEP\(_{\text{high}}\) of 10 cm H\(_2\)O above the baseline PEEP because of hemodynamic instability (mean arterial blood pressure <60 mm Hg). No pneumothoraces were observed. At 28 days, four patients died (26.7%), three patients were weaning from mechanical ventilation (20.0%), and eight patients were discharged from the ICU (53.3%).

PEEP\(_{\text{set}}\) was 2 cm H\(_2\)O (IQR, 0–5 cm H\(_2\)O) above the PEEP set by the higher PEEP–Fi\(_{\text{O}}\:_2\) table and 10 cm H\(_2\)O (IQR, 7–14 cm H\(_2\)O) above the PEEP set by the lower PEEP–Fi\(_{\text{O}}\:_2\) table (\(P = 0.01\) for the absolute difference) (Figure 2A). There was no correlation between PEEP\(_{\text{set}}\) and Fi\(_{\text{O}}\:_2\) (\(r = 0.11; P = 0.69\)). However, we did find a significant correlation between PEEP\(_{\text{set}}\) and BMI (\(r = 0.76; P = 0.001\)) (Figure 2B). PEEP\(_{\text{set}}\) did not change significantly over time (Figure 2C).

**Discussion**

In 15 patients with COVID-19–related ARDS, personalized PEEP at the level of lowest relative alveolar overdistention and collapse, as measured with EIT, resulted in high PEEP. These PEEP levels did not result in high driving pressure or transpulmonary pressure. In addition, PEEP trials did not result in relevant hemodynamic instability or pneumothorax. PEEP\(_{\text{set}}\) corresponded better with the higher PEEP–Fi\(_{\text{O}}\:_2\) table than the lower PEEP–Fi\(_{\text{O}}\:_2\) table and was positively correlated with BMI.

In COVID-19–related ARDS, both a low lung recruitability (L-type) and a high lung recruitability phenotype (H-type) have been described based on lung compliance and the amount of nonaerated lung tissue on lung CT scans (8). Especially in patients with the
### Table 1. Patient Characteristics

| Sex | Age (yr) | BMI (kg/m²) | APACHE IV Score | PaO₂/FIO₂ Ratio (mm Hg)\(^*\) | Baseline PEEP (cm H₂O)\(^†\) | Duration of MV (d)\(^‡\) | Prone Positioning\(^§\) | DP (cm H₂O)\(^k\) | Compliance (ml/cm H₂O) | CRP (mg/L)\(^**\) | ARDS Morphology |
|-----|---------|------------|----------------|-----------------------------|-----------------------------|--------------------------|-----------------|----------------------|------------------|---------------|----------------|
| F   | 49      | 42         | 79             | 68                          | 18                          | 8                        | Yes             | 12                   | 2                | 13            | 104 53 35 530 349 Diffuse |
| M   | 56      | 33         | 113            | 171                         | 20                          | 8                        | Yes             | 8                   | 0                | 8             | 90 165 58 Diffuse |
| M   | 65      | 27         | 94             | 54                          | 16                          | 2                        | Yes             | 10                  | 2                | 19            | 89 103 47 681 Diffuse |
| M   | 16      | 22         | 74             | 158                         | 15                          | 1                        | No              | N/A\(^††\)       | 6                | 19            | 52 92 33 157 Focal to diffuse |
| M   | 72      | 26         | 99             | 163                         | 16                          | 1                        | No              | 8                   | 4                | 12            | 114 175 69 673 Diffuse |
| F   | 59      | 28         | 73             | 116                         | 18                          | 1                        | Yes             | 10                  | 5                | 14            | 54 189 42 563 Diffuse |
| F   | 73      | 18         | 125            | 105                         | 16                          | 0                        | No              | 8                   | 2                | 10            | 82 134 51 401 Focal to diffuse |
| F   | 54      | 31         | 94             | 132                         | 16                          | 2                        | Yes             | 13                  | 3                | 16            | 43 180 35 526 Diffuse |
| M   | 53      | 31         | 67             | 186                         | 16                          | 1                        | Yes             | 7                   | 9                | 14            | 101 148 60 401 Diffuse |
| F   | 62      | 30         | 98             | 134                         | 12                          | 1                        | No              | 10                  | N/A\(^††\)       | N/A\(^††\)     | N/A\(^††\) 61 350 Focal to diffuse |
| M   | 66      | 36         | 124            | 118                         | 18                          | 1                        | No              | 4                   | 4                | 13            | 77 88 41 638 Focal |
| M   | 68      | 34         | 94             | 134                         | 18                          | 2                        | Yes             | 6                   | 1                | 14            | 124 77 47 280 Diffuse |
| M   | 56      | 34         | 101            | 148                         | 18                          | 2                        | Yes             | 7                   | N/A\(^††\)       | N/A\(^††\)     | N/A\(^††\) 69 331 Diffuse |
| M   | 61      | 29         | 124            | 140                         | 18                          | 1                        | Yes             | 7                   | 9                | 14            | 94 95 47 336 Diffuse |
| M   | 65      | 27         | 112            | 100                         | 16                          | 3                        | Yes             | 7                   | 5                | 9             | 102 146 60 386 Diffuse |

**Definition of abbreviations:** APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; BMI = body mass index; CRP = C-reactive protein; CW = chest wall; DP = driving pressure; Exp = expiratory; Insp = inspiratory; MV = mechanical ventilation; N/A = not available; PEEP = positive end-expiratory pressure; PL = transpulmonary pressure; RS = respiratory system.

*Lowest within 24 hours after ICU admission in our center.
†Baseline PEEP level at the moment of PaO₂/FIO₂ ratio measurement; baseline PEEP was set at the discretion of the attending clinician.
‡Number of days on MV at the day of the first PEEP trial.
§Received at least one session of prone positioning.
kHighest measured value (in cm H₂O) in the first 7 days of admission; DP was calculated as the difference between plateau pressure and total PEEP.
**Highest measured concentration in the first 3 days of admission.
††Unavailable because of loss of data.
‡‡Not available because of an unsuccessful attempt to place esophageal balloon catheter.
As a consequence, these patients with COVID-19 were likely to progress to diffuse ARDS, based on chest X-ray or lung CT scan. In addition, a secondary analysis of the ALVEOLI trial found that higher PEEP improved survival in patients with a hyperinflammatory ARDS phenotype (10). The hyperinflammatory phenotype could be predicted accurately using IL-6, tumor necrosis factor receptor, and vasopressors. Given the very high C-reactive protein concentrations and the use of vasopressors in all our patients, we assumed that the majority of patients in our study were in a hyperinflammatory state.

The LIVE trial predicted PEEP response based on lung morphology and found that patients with focal ARDS benefited from lower PEEP and that patients with diffuse ARDS benefited from higher PEEP (7). In our study, the majority of patients had or progressed to diffuse ARDS, based on chest X-ray or lung CT scan. As a consequence, these patients with COVID-19 were likely to respond to higher PEEP.

We realize that the availability of EIT is limited in ICUs worldwide. In clinical practice, the PEEP–FiO\textsubscript{2} table is often used because it is a simple approach to titrate PEEP. This study showed that PEEP\textsubscript{sat} at the level of lowest relative alveolar overdistention and collapse, as measured with EIT, corresponded better with the higher PEEP–FiO\textsubscript{2} table in 15 patients with COVID-19–related ARDS. However, the patients in our study had a high BMI, resulting in a lower transpulmonary pressure and increased PEEP requirement. Higher PEEP should be used with caution in patients with focal ARDS or low BMI. Moreover, response to higher PEEP should always be monitored in terms of driving pressure (2) or oxygenation (11).

**Author disclosures** are available with the text of this letter at www.atsjournals.org.

**Acknowledgment:** The authors thank all ICU personnel who enabled us to perform this study.

Philip van der Zee, M.D.*
Peter Somhorst, M.Sc.*
Henrik Endeman, M.D., Ph.D.
Diederik Gommers, M.D., Ph.D.
Erasmus Medical Center
Rotterdam, the Netherlands
ORCID ID: 0000-0002-5577-6848 (P.v.d.Z.).
*These authors contributed equally to this work.
‡Corresponding author (e-mail: p.vanderzee@erasusmc.nl).

**References**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
2. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015;372:747–755.
3. Cavalcanti AB, Suzumura EA, Laranjeira LN, Paisani DM, Damiani LP, Guimarães HP, et al.; Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs...
Severe coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leads to acute respiratory distress syndrome and hypoxic respiratory failure (1).

The University Hospital de la Santa Creu i Sant Pau serves an area of downtown Barcelona, Spain, of about 420,000 citizens. The first case of COVID-19 at our hospital was detected on March 17, 2020. The first two cases in the ICU were detected on March 13, and the number of beds dedicated to intensive care multiplied by four, with 163 new ICU admissions and 139 patients requiring mechanical ventilation between March 13 and April 4. During this period, 59 patients were discharged, 23 died, and 81 were still in the ICU.

BAL, bronchial wash, and protected specimen brush are bronchoscopic procedures used to provide microbiological samples from lower respiratory airways. However, because of the risk of viral transmission, bronchoscopy is not routinely indicated for the diagnosis of COVID-19 (2).

Bronchoscopy in critically ill patients with COVID-19 has been required to manage complications (atelectasis, hemoptysis, etc.) as well as to obtain samples for microbiological cultures and to assist in the management of artificial airways (guide intubation and percutaneous tracheostomy) (3).

Because no series of intubated patients with COVID-19 submitted to bronchoscopy has been published so far, we describe our experience in performing flexible bronchoscopies in patients with COVID-19 with severe acute hypoxemic respiratory failure requiring invasive mechanical ventilation during the first 3 weeks of the epidemic outbreak.

Between March 16 and April 4, 2020, a total of 101 bronchoscopies were performed in 93 patients with COVID-19. Eight patients required two bronchoscopies.

Indications for bronchoscopy were as follows: radiological and/or clinical deterioration suggesting possible superinfection (63/101) as well as airway secretion management with/without atelectasis (38/101). Intensivists indicated procedures 6.6 days (range, 1–17) after intubation. At the time of indication, the median FiO₂ was 0.8 (interquartile range [IQR], 0.67–0.82), the median positive end-expiratory pressure was 10 cm H₂O (IQR, 9–11), and the median PaO₂/FiO₂ ratio was 111 (IQR, 103–125).

Procedures were performed in either supine (74/101) or prone (27/101) position, under usual intravenous sedation and with pressure-controlled ventilation mode. Disposable scopes were used in all cases (Ambu aScope 4 Broncho, Large 5.8/2.8. Ambu A/S) and minimal staff attended the procedure bedside (one expert bronchoscopist occasionally accompanied by a staff intensivist). One out of two bronchoscopists got infected with SARS-CoV-2 and developed COVID-19. As a consequence, our colleague had to be replaced by another bronchoscopist during the third week.

Before the procedure, all the necessary equipment and materials were prepared outside the patient room, including saline, syringes, mucoactive drugs, microbiological recipients, connections, and bronchoscopy system (scope and screen). A negative-pressure room was not always available for the procedures owing to the variety of locations adapted for intensive care support. As recommended (2), level III of personal protective equipment was used, including N95 or FFP3 mask, goggles, double gloves, and a plastic protective gown including head and neck cover.

Bronchoscopic examination included orotracheal tube positioning check, direct inspection of tracheal and bronchial mucosa, suctioning of secretions, and mucoactive agent instillation if necessary (hypertonic saline combined with hyaluronic acid), and in 63 cases, a mini-BAL with 60-ml saline aliquots at room temperature was performed just before the end of procedure for microbiological sampling. The bronchial segment to